NCT04749602View on ClinicalTrials.gov

Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Renal Cell Cancer MetastaticNon-small Cell Lung Cancer MetastaticPleural Effusion, Malignant
Interventions
DRUG

Nivolumab

40 mg of the nivolumab will be used intrapleurally (once).

Trial Locations (5)

Unknown

I.M. Sechenov First Moscow State Medical University, Moscow

Kidney Cancer Research Bureau, Moscow

Medicine 24/7 clinic, Moscow

Medscan, Moscow

Yauza clinical hospital, Moscow

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER

NCT04749602 - Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | Biotech Hunter | Biotech Hunter